CRAYON
19.8.2020 06:02:10 CEST | Business Wire | Press release
Crayon, a global leader in digital transformation services, is proud to announce it has entered into a Strategic Collaboration Agreement with Amazon Web Services (AWS). This relationship will help both Crayon and AWS to bring innovation to clients faster, and help them best leverage the transformational power, economics, and agility of the cloud.
Enterprise customers are increasingly relying on AWS to achieve their target business outcomes faster by transitioning to a modern, optimized, cloud-based model. Crayon has a strong track record in migration strategy, implementation, total cost optimization, and cloud economics services. This relationship will help customers have a best-in-class service team to understand what software and infrastructure they have and how to best manage their overall IT estate once they are operating in the cloud.
According to global research and advisory firm Gartner Group, Inc. , spending on cloud infrastructure is projected to grow by nearly 60% in the next two years, while investments in data center systems is projected to decline. This means organizations will have to be smart about their IT investments. Crayon can provide the guidance, tools and expertise to properly manage costs, governance and security in the cloud.
“Collaborating with AWS has been a part of our strategy to build an even stronger commitment to our customers’ success. Alongside AWS we will deliver services to enable our customers to digitally transform, achieve operational efficiencies, and maximize cost optimization to strengthen their performance,” says Crayon CEO Torgrim Takle. “Putting the customer first is in the DNA of Crayon and AWS, and together we will serve more organizations worldwide with world-class solutions.”
Crayon has spent the last several years developing and diversifying its cloud services offerings. Both Crayon and AWS expect this latest collaboration to benefit customers wanting to optimize their overall IT estate utilizing best practices in their cloud adoption framework.
One of those customers who has seen first-hand the power of Crayon and AWS working together is The Future Group, a global company that handles many high-profile projects including those from The Weather Channel and the Super Bowl.
"At The Future Group we have had the great fortune to be able to draw on Crayon's deep knowledge in software development, cloud operations and AWS's wide range of services, to help us build and deliver one of the world's most advanced Mixed Reality solutions for the broadcast industry in record time," said Marcus Brodersen, CEO in The Future Group.
Crayon serves customers in more than 45 countries spanning Europe, the Middle East, Africa, North America, and the Asia-Pacific region.
“Crayon has demonstrated a longstanding commitment of putting customers first and helping them find effective ways to optimize the costs of their IT spend,” said Doug Yeum, Head of Worldwide Channel and Alliances, Amazon Web Services, Inc. “We are delighted to collaborate with Crayon to continue guiding customers through their cloud adoption journey.”
About Crayon:
Crayon helps customers build the commercial and technical foundation for a successful digital transformation journey through a reliable services framework allowing our customers to right-size and optimize their IT estates to unlock technology’s potential and innovation. Headquartered in Oslo, Norway, Crayon has over 1600 employees across approximately 50 locations worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005014/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom